Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000868586 | SCV001009933 | likely benign | Pancreatic adenocarcinoma | 2023-09-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004027730 | SCV003737654 | uncertain significance | not specified | 2021-09-10 | criteria provided, single submitter | clinical testing | The c.133C>A (p.P45T) alteration is located in exon 2 (coding exon 1) of the PALLD gene. This alteration results from a C to A substitution at nucleotide position 133, causing the proline (P) at amino acid position 45 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004751764 | SCV005349189 | uncertain significance | PALLD-related disorder | 2024-06-21 | no assertion criteria provided | clinical testing | The PALLD c.133C>A variant is predicted to result in the amino acid substitution p.Pro45Thr. This variant is referred to as c.1965-12898C>A (intronic) with an alternate transcript NM_016081. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.17% of alleles in individuals of Latino descent in gnomAD and has conflicting interpretations regarding its pathogenicity in ClinVar, ranging from uncertain to likely benign (https://www.ncbi.nlm.nih.gov/clinvar/variation/700415/). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |